The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies.
about
Electrospray ionization mass spectrometry of oligonucleotide complexes with drugs, metals, and proteins.Selective delivery of therapeutic agents for the diagnosis and treatment of cancer.Towards a ligand targeted enzyme prodrug therapy: single round panning of a beta-lactamase scaffold library on human cancer cells.Developing bifunctional beta-lactamase molecules with built-in target-recognizing module for prodrug therapy: identification of Enterobacter Cloacae P99 cephalosporinase loops suitable for randomization and phage-display selection.Novel beta-lactamase-random peptide fusion libraries for phage display selection of cancer cell-targeting agents suitable for enzyme prodrug therapyProdrug-activating systems in suicide gene therapy.Prodrug approaches for enhancing the bioavailability of drugs with low solubility.DNA-based therapeutics and DNA delivery systems: a comprehensive review.Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugatesDesign of anticancer prodrugs for reductive activation.Emerging implications of nonmammalian cytosine deaminases on cancer therapeutics.An overview of targeted cancer therapy.Magnetic nanoparticle hyperthermia induced cytosine deaminase expression in microencapsulated E. coli for enzyme-prodrug therapy.Inhibition of myc-dependent breast tumor formation in transgenic mice.Proteinous amino acids in muscle cytosol of rats' heart after exercise and hypoxia.
P2860
Q30688762-DB64BCF3-631D-4901-8668-7D814A74F8D1Q33230098-99BA57EE-47C3-4687-AF82-1DEC0FC0A061Q33272567-5B1418BA-2407-44E6-9C22-AF06A979F7BBQ33444939-9517E74B-88C5-4846-A810-251E34A27222Q33502835-B5EF9DA7-04C1-4936-B622-F6C009DEAA1CQ33904264-F38FE932-18E9-4C58-BD83-FFA98CE3F397Q35014488-CC0FA5F2-6532-4E21-AB72-1DA01DE2E89AQ36250777-9DEBAE25-C35A-4590-854E-C23B611C581AQ37000577-72A9C954-7319-4C75-9AEB-21BF44965312Q37238437-12E81DC0-E471-4475-8D63-4F8CA36A148AQ38016754-6837AABE-F002-4DCD-898D-7EF23F7BF755Q38650558-CC3520C4-9880-4FD2-BED8-187060A9D246Q38893603-7456ACEC-896F-47D5-8E59-B1CFD54926CAQ43892058-53AC4390-7CCE-4A5D-84B8-4AB833B482B2Q44607584-A6F687A8-9592-470F-813E-5559454665E5
P2860
The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
The design of selectively-acti ...... cted enzyme-prodrug therapies.
@en
The design of selectively-acti ...... cted enzyme-prodrug therapies.
@nl
type
label
The design of selectively-acti ...... cted enzyme-prodrug therapies.
@en
The design of selectively-acti ...... cted enzyme-prodrug therapies.
@nl
prefLabel
The design of selectively-acti ...... cted enzyme-prodrug therapies.
@en
The design of selectively-acti ...... cted enzyme-prodrug therapies.
@nl
P2860
P1476
The design of selectively-acti ...... cted enzyme-prodrug therapies.
@en
P2093
P2860
P304
P356
10.1111/J.2042-7158.1998.TB06878.X
P577
1998-04-01T00:00:00Z